Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ANON
MCID: ANR007
MIFTS: 68

Anorexia Nervosa (ANON)

Categories: Mental diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Anorexia Nervosa

About this section

MalaCards integrated aliases for Anorexia Nervosa:

Name: Anorexia Nervosa 57 12 76 75 55 44 15 73
Anorexia Nervosa, Susceptibility to, 1 57 13 40
Anorexia Nervosa, Susceptibility to 57 13
Anorexia Nervosa 1 57 29
Anon 57 75
an 57

Classifications:

MalaCards categories:
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

OMIM 57 606788
Disease Ontology 12 DOID:8689
ICD10 33 F50.0 F50.00
ICD9CM 35 307.1
MeSH 44 D000856
NCIt 50 C34387
SNOMED-CT 68 56882008
MedGen 42 C1853221
UMLS 73 C0003125
Sources

Summaries for Anorexia Nervosa

About this section
OMIM : 57 Eating disorders are characterized by severe disturbances in eating behavior that typically have onset during late adolescence and early adulthood. Three major types are recognized: anorexia nervosa (AN), bulimia nervosa (BN; 607499), and eating disorder not otherwise specified (EDNOS). AN is characterized by obsessive fear of weight gain, severely restricted eating, and low body weight. In women, AN has the highest mortality among the psychiatric disorders (Sullivan, 1995). AN is divided into 2 clinical subtypes, restricting anorexia nervosa (RAN) and binge-eating/purging anorexia nervosa (BPAN). BN can occur at any body weight and is characterized by binge-eating and compensatory weight-loss behaviors. Family studies have indicated an increased prevalence of eating disorders in relatives of probands with AN (Lilenfeld et al., 1998), and twin studies (Holland et al., 1984; Wade et al., 2000) have estimated concordance rates for monozygotic twins with AN to be 52 to 56%, whereas concordance rates for dizygotic twins with AN have been estimated to be 5 to 11% (Grice et al., 2002). (606788)

MalaCards based summary : Anorexia Nervosa, also known as anorexia nervosa, susceptibility to, 1, is related to acanthosis nigricans and eating disorder, and has symptoms including decrease in appetite An important gene associated with Anorexia Nervosa is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Fluoxetine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and heart, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Disease Ontology : 12 An eating disorder characterized by refusal to maintain a healthy body weight, and an obsessive fear of gaining weight due to a distorted self image.

UniProtKB/Swiss-Prot : 75 Anorexia nervosa: An eating disorder characterized by the lack or loss of appetite, excess fear of becoming overweight, body image disturbance, significant weight loss, refusal to maintain minimal normal weight, and amenorrhea.

Wikipedia : 76 Anorexia nervosa, often referred to simply as anorexia, is an eating disorder characterized by low... more...

Sources

Related Diseases for Anorexia Nervosa

About this section

Diseases related to Anorexia Nervosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 10462)
# Related Disease Score Top Affiliating Genes
1 acanthosis nigricans 32.8 ADIPOQ IGF1 LEP PRL
2 eating disorder 32.3 ADIPOQ BDNF CCK CRH GHRL LEP
3 bulimia nervosa 31.5 BDNF CCK GHRL HTR2A LEP NPY
4 adenoma 31.5 GH1 IGF1 POMC PRL
5 traumatic brain injury 31.3 BDNF GH1 IGF1
6 anxiety 31.3 BDNF CRH HTR2A NPY SLC6A4
7 amenorrhea 31.2 CRH LEP POMC PRL
8 depression 31.2 BDNF CRH HTR2A SLC6A4
9 dyspepsia 31.2 CCK GHRL SLC6A4
10 mccune-albright syndrome 31.2 GH1 IGF1 PRL
11 laron syndrome 31.1 GH1 GHR IGF1
12 empty sella syndrome 31.1 GH1 IGF1 POMC PRL
13 sleep apnea 31.0 ADIPOQ GHRL HTR2A IGF1 LEP LEPR
14 fatty liver disease, nonalcoholic 1 31.0 ADIPOQ LEP RETN
15 psychotic disorder 31.0 BDNF HTR2A PRL SLC6A4
16 hypertension, essential 31.0 ADIPOQ LEP NPY POMC RETN
17 retrograde amnesia 31.0 POMC SLC6A4
18 polycystic ovary syndrome 31.0 IGF1 LEP PRL
19 turner syndrome 31.0 GH1 GHR IGF1
20 fibrous dysplasia 31.0 GH1 IGF1 PRL
21 coronary artery aneurysm 31.0 ADIPOQ LEP RETN
22 disease of mental health 31.0 BDNF CCK CRH HTR2A POMC SLC6A4
23 anovulation 31.0 IGF1 LEP PRL
24 irritable bowel syndrome 31.0 CCK CRH PYY SLC6A4
25 obsessive-compulsive disorder 30.9 BDNF CRH HTR2A PRL SLC6A4
26 personality disorder 30.9 BDNF HTR2A PRL SLC6A4
27 lipid metabolism disorder 30.9 ADIPOQ LEP RETN
28 3-hydroxyacyl-coa dehydrogenase deficiency 30.9 ADIPOQ GHRL LEP RETN
29 attention deficit-hyperactivity disorder 30.9 BDNF HTR2A NPY SLC6A4
30 intermittent explosive disorder 30.9 NPY PRL SLC6A4
31 substance dependence 30.9 BDNF POMC SLC6A4
32 hyperprolactinemia 30.9 GH1 IGF1 POMC PRL
33 atypical depressive disorder 30.9 CRH HTR2A SLC6A4
34 gestational diabetes 30.9 ADIPOQ LEP RETN
35 postpartum depression 30.8 BDNF CRH PRL SLC6A4
36 hyperandrogenism 30.8 IGF1 POMC PRL
37 chiasmal syndrome 30.8 POMC PRL
38 fibromyalgia 30.8 CRH HTR2A IGF1 NPY PRL SLC6A4
39 pseudohypoparathyroidism, type ia 30.8 GH1 IGF1 PRL
40 uremia 30.8 GHR LEP RETN
41 pituitary tumors 30.8 GH1 IGF1 POMC PRL
42 isolated growth hormone deficiency, type ii 30.7 GH1 GHR GHRH IGF1
43 gigantism 30.7 GH1 GHRH PRL
44 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 30.7 LEP POMC
45 nonalcoholic fatty liver disease 30.7 ADIPOQ LEP RETN
46 pancreas disease 30.7 CCK IGF1 LEP POMC
47 panic disorder 30.6 BDNF CCK CRH GHRH HTR2A POMC
48 schizophrenia 30.6 BDNF CCK HTR2A NPY PRL SLC6A4
49 borderline personality disorder 30.6 BDNF HTR2A SLC6A4
50 acromegaly 30.5 GH1 GHR GHRH GHRL IGF1 POMC

Comorbidity relations with Anorexia Nervosa via Phenotypic Disease Network (PDN):


Acute Cystitis Major Depressive Disorder
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Anorexia Nervosa:



Diseases related to Anorexia Nervosa
Sources

Symptoms & Phenotypes for Anorexia Nervosa

About this section

Clinical features from OMIM:

606788

UMLS symptoms related to Anorexia Nervosa:


decrease in appetite

GenomeRNAi Phenotypes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 AGRP BDNF GHR GHRL IGF1 POMC

MGI Mouse Phenotypes related to Anorexia Nervosa:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 ADIPOQ AGRP BDNF CCK CRH GHR
2 homeostasis/metabolism MP:0005376 10.39 ADIPOQ AGRP BDNF CCK CRH GHR
3 endocrine/exocrine gland MP:0005379 10.34 ADIPOQ BDNF CCK CRH GHR GHRH
4 adipose tissue MP:0005375 10.3 ADIPOQ AGRP CRH GHR GHRL IGF1
5 growth/size/body region MP:0005378 10.29 ADIPOQ AGRP BDNF CRH GHR GHRH
6 liver/biliary system MP:0005370 10.14 ADIPOQ AGRP CRH GHR GHRH LEP
7 integument MP:0010771 10.13 ADIPOQ BDNF CRH GHR IGF1 LEP
8 nervous system MP:0003631 10.13 ADIPOQ AGRP BDNF CCK CRH GHR
9 muscle MP:0005369 9.91 ADIPOQ GHR HTR2A IGF1 LEP LEPR
10 normal MP:0002873 9.81 AGRP BDNF CRH GHRL IGF1 LEPR
11 neoplasm MP:0002006 9.8 ADIPOQ IGF1 LEP LEPR POMC PRL
12 renal/urinary system MP:0005367 9.61 ADIPOQ CCK CRH GHR IGF1 LEP
13 skeleton MP:0005390 9.28 ADIPOQ CRH GHR HTR2A IGF1 LEP
Sources

Drugs & Therapeutics for Anorexia Nervosa

About this section

Drugs for Anorexia Nervosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluoxetine Approved, Vet_approved Phase 4,Not Applicable 54910-89-3 3386
2
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
3
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 132539-06-1 4585
4
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
5
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
6
Hydroxyzine Approved Phase 4 68-88-2 3658
7
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
8
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
9
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
10 Raclopride Investigational Phase 4 84225-95-6
11 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
13 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
17 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
18 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Cytochrome P-450 Enzyme Inhibitors Phase 4,Not Applicable
20 Antidepressive Agents Phase 4,Not Applicable
21 Antidepressive Agents, Second-Generation Phase 4,Not Applicable
22 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Not Applicable
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
26 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
27 Dopamine Agents Phase 4,Not Applicable
28 Serotonin Antagonists Phase 4
29 Dopamine Antagonists Phase 4
30
Histamine Phosphate Phase 4 51-74-1 65513
31 Dermatologic Agents Phase 4
32 Antipruritics Phase 4
33 Histamine H1 Antagonists Phase 4
34 Histamine Antagonists Phase 4
35 Sympathomimetics Phase 4,Not Applicable
36 Adrenergic Agents Phase 4,Not Applicable
37 Dopamine Uptake Inhibitors Phase 4
38 Central Nervous System Stimulants Phase 4
39
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-67-9 5202
40
Teriparatide Approved, Investigational Phase 3,Phase 2 52232-67-4 16133850
41 tannic acid Approved Phase 3
42
Mecasermin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68562-41-4
43
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-28-2 5757
44
Polyestradiol phosphate Approved Phase 3,Phase 2,Phase 1 28014-46-2
45
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
46
Progesterone Approved, Vet_approved Phase 3,Phase 2 57-83-0 5994
47 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 979-32-8
48
Ethinyl Estradiol Approved Phase 2, Phase 3,Phase 3 57-63-6 5991
49
Medroxyprogesterone acetate Approved, Investigational Phase 2, Phase 3,Phase 1 71-58-9
50
Denosumab Approved Phase 3,Early Phase 1 615258-40-7

Interventional clinical trials:

(show top 50) (show all 235)
# Name Status NCT ID Phase Drugs
1 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
2 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
3 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
4 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
5 Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
6 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
7 ARIpiprazole in Anorexia NErvosa Unknown status NCT01082848 Phase 3 aripiprazole;placebo
8 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
9 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
10 Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa Completed NCT01823822 Phase 2, Phase 3
11 Effects of Anorexia Nervosa on Peak Bone Mass Recruiting NCT01301183 Phase 3 RhIGF-1 with transdermal 17-beta estradiol;Placebo and transdermal 17-beta estradiol
12 Effects of Anorexia Nervosa on Bone Mass in Adolescents Completed NCT00088153 Phase 2, Phase 3 Physiologic Estrogen/progesterone
13 Comparison of Two Types of Family Therapy in the Treatment of Adolescent Anorexia Nervosa Completed NCT00610753 Phase 3
14 Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa Terminated NCT02567279 Phase 3 Denosumab subcutaneous injections;Placebo subcutaneous injections
15 The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa Completed NCT02004288 Phase 2, Phase 3
16 Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa Completed NCT00310791 Phase 2, Phase 3 Hormone replacement therapy (estrogen/progestin);Dehydroepiandrosterone (DHEA)
17 Bone Loss in Women With Anorexia Nervosa Completed NCT00089843 Phase 2, Phase 3 Testosterone;Actonel (risedronate);Placebo Actonel (risedronate);Placebo testosterone
18 Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone Active, not recruiting NCT01626833 Phase 2, Phase 3 SOMATROPINE* : Norditropine® simplexx®
19 Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa Completed NCT00760695 Phase 3 dronabinol;placebo
20 Hormonal Therapy for Teens With Anorexia Nervosa Completed NCT01343771 Phase 3 DHEA (Prasterone) + ERT (Aviane)
21 Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents Terminated NCT01184443 Phase 3 Olanzapine
22 Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa Unknown status NCT01761942 Phase 2
23 Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa Unknown status NCT01611220 Phase 2
24 Therapeutic Effects of Neurofeedback in Anorexia Nervosa Completed NCT01390493 Phase 1, Phase 2
25 Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa Completed NCT01642550 Phase 2 RM-131;Placebo
26 A Relapse Prevention Program for Reducing Relapse and Fear of Food in People With Anorexia Nervosa Completed NCT00627341 Phase 1, Phase 2
27 A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study Terminated NCT00584688 Phase 2 quetiapine
28 Treatment of Anxiety and Anorexia Nervosa in Adolescents Completed NCT01933243 Phase 2 Fish oil;Placebo pill
29 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa Completed NCT02475265 Phase 2 estradiol 0.045 mg/levonorgestrel 0.015mg
30 Estrogen Replacement in Anorexia Nervosa Recruiting NCT03172533 Phase 2 ethinyl estradiol 0.03mg and dienogest 2 mg (combination);Placebo oral capsule
31 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa Completed NCT00759772 Phase 2 Placebo;Teriparatide
32 Olanzapine in the Treatment of Patients With Anorexia Nervosa Completed NCT00260962 Phase 2 Olanzapine
33 Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa Completed NCT00692185 Phase 2 Olanzapine;Placebo
34 Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa Completed NCT00720122 Phase 2 Recombinant human insulin like growth factor-1 (rhIGF-1)
35 Hormonal Factors in the Treatment of Anorexia Nervosa Completed NCT01121211 Phase 2 Testosterone;Placebo
36 Comparing the Effectiveness of Three Types of Therapy for the Treatment of Anorexia Nervosa in Adolescents Completed NCT00183586 Phase 2
37 Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa Completed NCT00283595 Phase 2 Recombinant Human Growth Hormone;Placebo for Recombinant Human Growth Hormone
38 The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa Completed NCT00320567 Phase 2 norgestimate/ethinyl estradiol
39 The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa Withdrawn NCT00853502 Phase 2 testosterone cypionate
40 Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents Completed NCT00516386 Phase 1, Phase 2 RhIGF-1
41 Amino Acids, Serotonin, and Body Weight Regulation Completed NCT00343928 Phase 2
42 The Role of Estrogen in the Neurobiology of Eating Disorders Not yet recruiting NCT03740204 Phase 2 17-β estradiol transdermal patches with cyclic progesterone;Placebo patch and pill
43 Look at Food and Lose Your Fear - Evaluation of a Computerized Attention Training (CAT) for Anorexia Nervosa Patients Unknown status NCT02484599 Phase 1
44 Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01476540 Phase 1
45 Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01678014 Phase 1
46 Yoga in Treatment of Eating Disorders Unknown status NCT00870753 Phase 1
47 Effectiveness of Cognitive Remediation Therapy in Improving Treatment Retention in People With Anorexia Nervosa Completed NCT00601822 Phase 1
48 Estradiol and Fear Extinction in Anorexia Nervosa (AN) Withdrawn NCT02792153 Phase 1 Estradiol
49 Family Treatment for Adolescents With Anorexia Nervosa Completed NCT01280799 Phase 1
50 Effectiveness of Family-Based Versus Individual Psychotherapy in Treating Adolescents With Anorexia Nervosa Completed NCT00149786 Phase 1

Search NIH Clinical Center for Anorexia Nervosa

Cochrane evidence based reviews: anorexia nervosa

Sources

Genetic Tests for Anorexia Nervosa

About this section

Genetic tests related to Anorexia Nervosa:

# Genetic test Affiliating Genes
1 Anorexia Nervosa 1 29 HTR2A
Sources

Anatomical Context for Anorexia Nervosa

About this section

MalaCards organs/tissues related to Anorexia Nervosa:

41
Bone, Brain, Heart, Testes, Cortex, Pituitary, Skin
Sources

Publications for Anorexia Nervosa

About this section

Articles related to Anorexia Nervosa:

(show top 50) (show all 2332)
# Title Authors Year
1
The paradox of marrow adipose tissue in anorexia nervosa. ( 29458121 )
2019
2
Role of antidepressants in the treatment of adults with anorexia nervosa. ( 29955558 )
2018
3
Do eating disorder voice characteristics predict treatment outcomes in anorexia nervosa? A pilot study. ( 29882721 )
2018
4
Do autism spectrum disorder and anorexia nervosa have some eating disturbances in common? ( 29974245 )
2018
5
Associations between exercise, bone mineral density, and body composition in adolescents with anorexia nervosa. ( 29949128 )
2018
6
Anorexia Nervosa, Selflessness, and Gender-role Identity: A Study of Daughters and Parents. ( 29916404 )
2018
7
The QT Interval in Anorexia Nervosa: A Meta-Analysis. ( 29929679 )
2018
8
Anorexia nervosa-associated pancytopenia mimicking idiopathic aplastic anemia: a case report. ( 29801443 )
2018
9
The role of maternal anorexia nervosa and bulimia nervosa before and during pregnancy in early childhood wheezing: Findings from the NINFEA birth cohort study. ( 29722053 )
2018
10
Women with Anorexia Nervosa do not show altered tactile localization compared to healthy controls. ( 29980123 )
2018
11
In Reply: Long-Term Follow-up Study of MRI-Guided Bilateral Anterior Capsulotomy in Patients With Refractory Anorexia Nervosa. ( 29912441 )
2018
12
White matter microstructure in anorexia nervosa. ( 29964345 )
2018
13
Testing the relative associations of different components of dietary restraint on psychological functioning in anorexia nervosa and bulimia nervosa. ( 29807122 )
2018
14
Locating the mechanisms of therapeutic agency in family-based treatment for adolescent anorexia nervosa: A pilot study of clinician/researcher perspectives. ( 29863443 )
2018
15
Differential Diagnoses of Food-Related Gastrointestinal Symptoms in Patients with Anorexia Nervosa and Bulimia Nervosa: A Review of Literature. ( 29498331 )
2018
16
Bone Parameters in Anorexia Nervosa and Athletic Amenorrhea: Comparison of Two Hypothalamic Amenorrhea States. ( 29659886 )
2018
17
Non-weight-related body image concerns and Body Dysmorphic Disorder prevalence in patients with Anorexia Nervosa. ( 29886274 )
2018
18
Validation of the Inventory of Interpersonal Problems (IIP-64): a comparison of Swedish female outpatients with anorexia nervosa or bulimia nervosa and controls. ( 29703121 )
2018
19
Symptomatology long-term evolution after hospitalization for anorexia nervosa: Drive for thinness to explain effects of body dissatisfaction on type of outcome. ( 29859637 )
2018
20
Associations among eating disorder behaviors and eating disorder quality of life in adult women with anorexia nervosa. ( 29886272 )
2018
21
Feeling fat in eating disorders: Testing the unique relationships between feeling fat and measures of disordered eating in anorexia nervosa and bulimia nervosa. ( 29653375 )
2018
22
Variation in reproductive outcomes of women with histories of bulimia nervosa, anorexia nervosa, or eating disorder not otherwise specified relative to the general population and closest-aged sisters. ( 29331083 )
2018
23
Letter: Long-Term Follow-up Study of MRI-Guided Bilateral Anterior Capsulotomy in Patients With Refractory Anorexia Nervosa. ( 29912370 )
2018
24
Nutritional Status Affects Cortical Folding: Lessons Learned From Anorexia Nervosa. ( 29910027 )
2018
25
Deranged emotional and cortisol responses to a psychosocial stressor in anorexia nervosa women with childhood trauma exposure: Evidence for a "maltreated ecophenotype"? ( 29936175 )
2018
26
Core psychopathology in anorexia nervosa and bulimia nervosa: A network analysis. ( 29693747 )
2018
27
The Impact of Alexithymia on Emotion Dysregulation in Anorexia Nervosa and Bulimia Nervosa over Time. ( 29266572 )
2018
28
Altered cerebellar-insular-parietal-cingular subnetwork in adolescents in the earliest stages of anorexia nervosa: a network-based statistic analysis. ( 29980676 )
2018
29
Implementation of enhanced cognitive behaviour therapy (CBT-E) for adults with anorexia nervosa in an outpatient eating-disorder unit at a public hospital. ( 29854400 )
2018
30
Clinical characteristics of early onset anorexia nervosa. ( 29943460 )
2018
31
Effects of starvation and short-term refeeding on gastric emptying and postprandial blood glucose regulation in adolescent females with anorexia nervosa. ( 29969316 )
2018
32
Problems of control: Alcohol dependence, anorexia nervosa, and the flexible interpretation of mental incapacity tests. ( 30053254 )
2018
33
Emotional intelligence, empathy and alexithymia in anorexia nervosa during adolescence. ( 29453591 )
2018
34
Factorial Validity of the Toronto Alexithymia Scale (TAS-20) in Clinical Samples: A Critical Examination of the Literature and a Psychometric Study in Anorexia Nervosa. ( 29603033 )
2018
35
Bone metabolism in anorexia nervosa and hypothalamic amenorrhea. ( 29107598 )
2018
36
Structural alterations in the caudate nucleus and precuneus in un-medicated anorexia nervosa patients. ( 30212787 )
2018
37
Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients. ( 30214813 )
2018
38
Disorder-specific attachment characteristics and experiences of childhood abuse and neglect in adolescents with anorexia nervosa and a major depressive episode. ( 30216616 )
2018
39
Anorexia nervosa or starvation? ( 30218629 )
2018
40
The Role of Objectively Measured, Altered Physical Activity Patterns for Body Mass Index Change during Inpatient Treatment in Female Patients with Anorexia Nervosa. ( 30231527 )
2018
41
Women's recovery from anorexia nervosa: a systematic review and meta-synthesis of qualitative research. ( 30247988 )
2018
42
Abnormal brain processing of gentle touch in anorexia nervosa. ( 30248526 )
2018
43
Resting state functional connectivity of networks associated with reward and habit in anorexia nervosa. ( 30251758 )
2018
44
Adiponectin and resistin in acutely ill and weight-recovered adolescent anorexia nervosa: Association with psychiatric symptoms. ( 30264643 )
2018
45
Time trends in healthcare-detected incidence of anorexia nervosa and bulimia nervosa in the Norwegian National Patient Register (2010-2016). ( 30265747 )
2018
46
Eating Pathology Among Patients With Anorexia Nervosa and Bulimia Nervosa: The Role of Narcissism and Self-Esteem. ( 30273274 )
2018
47
Challenges of anorexia nervosa in adolescence: ethnography in a public health service of Rio de Janeiro, Brazil. ( 30281730 )
2018
48
Relationship between serum level of growth differentiation factors 8, 11 and bone mineral density in girls with anorexia nervosa. ( 30281844 )
2018
49
Exercise, diet, and the reinforcing value of food in an animal model of anorexia nervosa. ( 30282528 )
2018
50
The Anorexia Nervosa Genetics Initiative (ANGI): Overview and methods. ( 30287268 )
2018
Sources

Variations for Anorexia Nervosa

About this section
Sources

Expression for Anorexia Nervosa

About this section
Search GEO for disease gene expression data for Anorexia Nervosa.
Sources

Pathways for Anorexia Nervosa

About this section

Pathways related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 66
Show member pathways
 13.04 CCK CRH GH1 GHR GHRH GHRL
2
G-Beta Gamma Signaling 64
Show member pathways
 12.84 BDNF CRH GH1 GHRH HTR2A POMC
3
Prolactin Signaling Pathway 1 37
Show member pathways
 12.29 GH1 LEP LEPR PRL
4
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.24 ADIPOQ IGF1 LEP LEPR
5
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.17 GH1 GHR LEP LEPR PRL
7
Peptide hormone metabolism 66
Show member pathways
 11.98 GH1 GHRL IGF1 LEP POMC
8
Adipogenesis 1
11.78 ADIPOQ GH1 IGF1 LEP RETN
9
G-protein signaling_RhoA regulation pathway 22
11.54 BDNF GH1 GHRH IGF1
10
Endochondral Ossification 1
11.5 GH1 GHR IGF1
11
Signaling events mediated by PTP1B 1
11.33 LEP LEPR PRL
12
Growth hormone receptor signaling 66
Show member pathways
 11.22 GH1 GHR PRL
13
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 11.02 LEP LEPR POMC
14
Adipocytokine signaling pathway 37
10.94 ADIPOQ AGRP LEP LEPR NPY POMC
15
Syndecan-3-mediated signaling events 1
10.79 AGRP POMC
16
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 61
10.32 CRH POMC
Sources

GO Terms for Anorexia Nervosa

About this section

Cellular components related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 ADIPOQ AGRP BDNF CCK CRH GH1
2 neuronal cell body GO:0043025 9.65 AGRP CCK CRH GHR HTR2A
3 extracellular space GO:0005615 9.53 ADIPOQ AGRP BDNF CCK CRH GH1
4 endosome lumen GO:0031904 9.32 GH1 PRL
5 growth hormone receptor complex GO:0070195 9.16 GH1 GHR

Biological processes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 CCK CRH GHRH HTR2A IGF1 LEP
2 response to hypoxia GO:0001666 9.96 ADIPOQ GHRH LEP SLC6A4
3 response to ethanol GO:0045471 9.91 ADIPOQ CRH LEP PRL
4 glucose homeostasis GO:0042593 9.91 ADIPOQ LEP LEPR POMC
5 female pregnancy GO:0007565 9.89 CRH LEP PRL
6 response to estradiol GO:0032355 9.88 GH1 LEP PRL SLC6A4
7 neuropeptide signaling pathway GO:0007218 9.88 AGRP NPY POMC PYY
8 response to insulin GO:0032868 9.87 AGRP LEP RETN
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.87 GH1 IGF1 LEP
10 regulation of blood pressure GO:0008217 9.86 LEP NPY POMC
11 glucose metabolic process GO:0006006 9.85 ADIPOQ GHRL LEP
12 positive regulation of cold-induced thermogenesis GO:0120162 9.84 ADIPOQ GHRL LEP LEPR
13 hormone-mediated signaling pathway GO:0009755 9.83 AGRP GHR GHRL
14 response to nutrient GO:0007584 9.83 ADIPOQ LEP PRL SLC6A4
15 memory GO:0007613 9.81 BDNF CCK HTR2A SLC6A4
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 GH1 GHR IGF1 LEP
17 feeding behavior GO:0007631 9.79 AGRP NPY PYY
18 regulation of multicellular organism growth GO:0040014 9.77 GHR IGF1 PRL
19 circadian rhythm GO:0007623 9.77 ADIPOQ AGRP LEP PRL SLC6A4
20 energy reserve metabolic process GO:0006112 9.72 LEP LEPR
21 hormone metabolic process GO:0042445 9.72 GHR LEP
22 negative regulation of gluconeogenesis GO:0045721 9.72 ADIPOQ LEPR
23 eating behavior GO:0042755 9.72 AGRP CCK LEP
24 central nervous system neuron development GO:0021954 9.71 LEP NPY
25 insulin-like growth factor receptor signaling pathway GO:0048009 9.71 GHR IGF1
26 growth hormone receptor signaling pathway GO:0060396 9.71 GH1 GHR
27 positive regulation of growth GO:0045927 9.71 GH1 GHRL
28 regulation of feeding behavior GO:0060259 9.71 AGRP LEPR
29 positive regulation of multicellular organism growth GO:0040018 9.71 GH1 GHR GHRH GHRL
30 parturition GO:0007567 9.7 CRH PRL
31 response to leptin GO:0044321 9.7 GHRH LEPR
32 sexual reproduction GO:0019953 9.7 LEP LEPR
33 leptin-mediated signaling pathway GO:0033210 9.69 LEP LEPR
34 negative regulation of appetite GO:0032099 9.69 CCK LEP
35 positive regulation of growth hormone secretion GO:0060124 9.68 GHRH GHRL
36 growth hormone secretion GO:0030252 9.68 GHRH GHRL
37 positive regulation of feeding behavior GO:2000253 9.67 AGRP GHRL
38 positive regulation of behavioral fear response GO:2000987 9.67 CCK CRH
39 regulation of bone remodeling GO:0046850 9.67 LEP LEPR
40 bone mineralization involved in bone maturation GO:0035630 9.65 IGF1 LEP
41 negative regulation of glucagon secretion GO:0070093 9.65 CRH LEP
42 positive regulation of circadian sleep/wake cycle, non-REM sleep GO:0046010 9.65 GHRH GHRL
43 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.65 GH1 GHR PRL
44 response to nutrient levels GO:0031667 9.65 ADIPOQ GH1 GHRL LEP PRL
45 positive regulation of corticotropin secretion GO:0051461 9.64 CRH GHRL
46 positive regulation of cortisol secretion GO:0051464 9.64 CRH GHRL
47 positive regulation of appetite GO:0032100 9.63 GHRL NPY
48 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.63 GH1 GHRH IGF1
49 positive regulation of lactation GO:1903489 9.62 GHRH PRL
50 positive regulation of JAK-STAT cascade GO:0046427 9.62 GH1 GHR LEP PRL

Molecular functions related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.8 ADIPOQ AGRP CRH LEP NPY POMC
2 G protein-coupled receptor binding GO:0001664 9.56 GHRL NPY POMC PYY
3 hormone activity GO:0005179 9.44 ADIPOQ CCK CRH GH1 GHRH GHRL
4 serotonin binding GO:0051378 9.43 HTR2A SLC6A4
5 neuropeptide hormone activity GO:0005184 9.43 AGRP CCK CRH GHRH NPY PYY
6 growth hormone-releasing hormone activity GO:0016608 9.4 GHRH GHRL
7 prolactin receptor binding GO:0005148 9.37 GH1 PRL
8 peptide hormone receptor binding GO:0051428 9.33 CCK GHRH LEP
Sources

Sources for Anorexia Nervosa

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....